Abstract
Background: Early initiation of disease-modifying treatment (DMT) is associated with better disability outcomes in multiple sclerosis (MS). However, little is known of how treatment decisions affect socio-economic outcomes. Objective: To estimate the long-term impact of early initiation of DMT on the income of MS patients. Methods: In total, 3610 MS patients were included in this register-based cohort study. We measured the association between the time to treatment and the outcome, defined as time from treatment initiation to a 95% decrease in annual earnings compared to each patient´s baseline level. Additionally, the association between time to treatment and increase of social benefits (sickness absence, disability pension) was investigated. A Cox model was adjusted for sex, onset age, education, family situation, country of birth, living area, and disability. Results: MS patients initiating treatment later had a higher risk of reaching the outcome- those who started treatment after 2 years from MS onset lost 95% of their earnings sooner (HR, 1.19; 95% CI, 1.04–1.37). Furthermore, risk to receive an annual compensation of SEK 100,000 (≈EUR 10,500) was higher for the delayed treatment group. Conclusion: Early treatment initiation in MS is associated with better socioeconomic outcome, adding to previous studies showing benefits regarding disability.
Author supplied keywords
Cite
CITATION STYLE
Kavaliunas, A., Manouchehrinia, A., Gyllensten, H., Alexanderson, K., & Hillert, J. (2020). Importance of early treatment decisions on future income of multiple sclerosis patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 6(4). https://doi.org/10.1177/2055217320959116
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.